Intervacc AB engages in the development of novel veterinary vaccines. It markets veterinary vaccines through its subsidiary Nordvacc Läkemedel AB. The company was founded by Jan-Ingmar Flock, Bengt Guss, Kenneth Janzon, and Rune Bergman in 2001 and is headquartered in Stockholm, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company